
Brand Name | Status | Last Update |
|---|---|---|
| diskets | New Drug Application | 2023-12-01 |
| diskets dispersible | 2007-08-03 | |
| methadone | 2007-10-06 | |
| methadone hcl | 2008-05-08 | |
| methadone hydrochloride | ANDA | 2025-09-09 |
| methadone hydrochloride methadose | 2006-09-19 | |
| methadone hydrochloride methadose dispersible | ANDA | 2024-06-28 |
| methadone hydrocloride | ANDA | 2025-05-29 |
| methadose | New Drug Application | 2024-07-24 |
| methadose methadose | New Drug Application | 2011-01-28 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | 1 | — | — | 1 |
| Morphine dependence | D009021 | EFO_0005612 | — | — | — | 1 | — | — | 1 |
| Opiate substitution treatment | D058850 | — | — | — | — | 1 | — | — | 1 |
| Drug common name | Esmethadone |
| INN | esmethadone |
| Description | Dextromethadone is a 6-(dimethylamino)-4,4-diphenylheptan-3-one that has (S)-configuration. It is the less active enantiomer of methadone and has very little activity on opioid receptors and mainly responsible for the inhibition of hERG K+ channels and thus for cardiac toxicity. The drug is currently under clinical development for the treatment of major depressive disorder. It has a role as a NMDA receptor antagonist and an opioid analgesic. It is an enantiomer of a levomethadone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)C(C[C@H](C)N(C)C)(c1ccccc1)c1ccccc1 |
| PDB | — |
| CAS-ID | 5653-80-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL350719 |
| ChEBI ID | — |
| PubChem CID | 643985 |
| DrugBank | DB15198 |
| UNII ID | S95RZH8AMH (ChemIDplus, GSRS) |
